Ceramics Manufacturing Contributes to Ambient Silica Air Pollution and Burden of Lung Disease
Overview
Toxicology
Affiliations
Inhalation of silica (SiO2) in occupational exposures can cause pulmonary fibrosis (silicosis), lung function deficits, pulmonary inflammation, and lung cancer. Current risk assessment models, however, cannot fully explain the magnitude of silica-induced pulmonary disease risk. The purpose of this study was to assess human health risk exposed to airborne silica dust in Taiwan ceramics manufacturing. We conducted measurements to characterize workplace-specific airborne silica dust in tile and commodity ceramic factories and used physiologically based alveolar exposure model to estimate exposure dose. We constructed dose-response models for describing relationships between exposure dose and inflammatory responses, by which health risks among workers can be assessed. We found that silica contents were 0.22-33.04 % with mean concentration ranges of 0.11-5.48 and 0.46-1763.30 μg m(-3), respectively, in commodity and tile ceramic factories. We showed that granulation workers in tile ceramic factory had the highest total SiO2 lung burden (∼1000 mg) with cumulative SiO2 lung burden of ∼4 × 10(4) mg-year. The threshold estimates with an effect on human lung inflammation and fibrosis are 407.31 ± 277.10 (mean ± sd) and 505.91 ± 231.69 mg, respectively. For granulation workers, long-term exposure to airborne silica dust for 30-45 years was likely to pose severe adverse health risks of inflammation and fibrosis. We provide integrated assessment algorithms required to implement the analyses and maintain resulting concentration of silica dust at safety threshold level in the hope that they will stimulate further analyses and interpretation. We suggest that decision-makers take action to implement platforms for effective risk management to prevent the related long-term occupational disease in ceramics manufacturing.
Risk assessment methods in occupational health and hygiene: a scoping review.
Floeder A, Jones R, Arnold S Ann Work Expo Health. 2024; 69(2):120-131.
PMID: 39705502 PMC: 11858558. DOI: 10.1093/annweh/wxae095.
Lin Y, Yang C, Lee I, Wu W, Lin C, Hsiao L Biomedicines. 2023; 11(10).
PMID: 37893002 PMC: 10604097. DOI: 10.3390/biomedicines11102628.
A Descriptive Study of a Turkish Pneumoconiosis Case-Series.
Sari G, Simsek C Med Lav. 2023; 114(1):e2023003.
PMID: 36790410 PMC: 9987468. DOI: 10.23749/mdl.v114i1.13215.
Yang Y, Wang W, Chen C, Lu T, Liao C Int J Nanomedicine. 2019; 14:1687-1703.
PMID: 30880973 PMC: 6407905. DOI: 10.2147/IJN.S171510.
Abad A, Gerassis S, Saavedra A, Giraldez E, Garcia J, Taboada J Environ Sci Pollut Res Int. 2018; 26(29):29560-29569.
PMID: 30121763 DOI: 10.1007/s11356-018-2962-6.